Recent Updates
Recently added Catalysts

ACT-293987

Phase 3

Pulmonary Arterial Hypertension | Unknown | Cardiovascular |Johnson & Johnson|Last Updated: Sep 12, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedUNCONTROLLEDDMCBiomarker
Total Trials2
Total Enrollment752
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01112306ACT-293987 in Pulmonary Arterial HypertensionPHASE3 COMPLETED 709Jul 7, 2010Aug 26, 2021Mar 30, 2025157 United States, Argentina +36
NCT00993408Study of ACT-293987 (NS-304) in Pulmonary Arterial Hypertension (PAH)PHASE2 COMPLETED 43Apr 30, 2008Jun 30, 2009Sep 12, 20258 Austria, Belgium +6
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants With Treatment-emergent Adverse Events (TEAEs) up to 3 Days After Study Intervention Discontinuation
Up to 3 days after study drug discontinuation (Up to 10.5 years)

An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. A TEAE is any AE temporally associated with the use of study drug (from study drug initiation until 3 days after study drug discontinuation), whether or not considered related to the study drug.

Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) up to 3 Days After Study Intervention Discontinuation
Up to 3 days after study drug discontinuation (Up to 10.5 years)

An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above. Those SAEs occurring during study drug administration, that is, between study drug initiation and three days after study drug discontinuation, are defined as treatment-emergent SAEs.

Number of Participants With TEAEs Leading to Permanent Discontinuation of Study Intervention
Up to 10.5 years

An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. A TEAE is any AE temporally associated with the use of study drug (from study drug initiation until 3 days after study drug discontinuation), whether or not considered related to the study drug.

Assessment of hemodynamic parameters after single oral dose of ACT-293987.
17 weeks
Proof-of-concept assessment of the efficacy of ACT-293987 in subjects with PAH by measuring the change from baseline in the PVR at Week 17 compared to placebo.
17 weeks
Secondary Endpoints
Percentage of Alive Participants
Baseline (Day 1), Months 3, 6, 9, 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Safety and tolerability of a single oral dose of ACT-293987.
17 weeks
Assessments of preliminary efficacy of ACT-293987 regarding 6 minute walk test (6MWT), proportion of subjects with aggravation of PAH, hemodynamic parameters other than PVR
17 weeks
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
1EXPERIMENTALACT-293987, twice daily
ACT-293987 (NS-304) and matching placeboEXPERIMENTALSubjects will be randomized to the study following screening. Each subject will then undergo an acute hemodynamic study with right heart catheterization after a single oral administration of ACT-293987 (NS-304)on Day 0. The objectives are to collect data about the drug effect on the right heart hemodynamic parameters (PVR, calculated SVR and PVR/SVR) measured by right heart catheterization after single oral dose administration of NS-304 and to assess the safety and tolerability of a single oral dose of NS-304.
Interventions
NameTypeDescription
ACT-293987DRUGTablets, twice daily
ACT-293987 (NS-304)DEVICE -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites157

Inclusion Criteria: * Patients who participated to the double-blind study AC-065A302 and either had a morbidity event or had completed the study as scheduled per protocol. * Signed informed consent. Exclusion Criteria: * Patients who have started receiving prostacyclin (epoprostenol) or prostacyc...

Countries:United StatesArgentinaAustraliaAustriaBelarusBelgiumCanadaChileChinaColombiaCzechiaDenmarkFranceGermanyGreeceHungaryIndiaIrelandIsraelMalaysiaMexicoNetherlandsPeruPolandRomaniaRussiaSerbiaSingaporeSlovakiaSouth KoreaSpainSwedenSwitzerlandTaiwanThailandTurkey (Türkiye)UkraineUnited KingdomItaly
Unlock Eligibility Criteria